-Livemint The development economist on the Modi government's initiatives and his stand on them, and MGNREGS The Narendra Modi-led government should consider replacing inefficient subsidies with a basic monthly income for all citizens, says Pranab Bardhan , emeritus professor of economics at the University of California at Berkeley. Bardhan, who recently sparred with economists Jagdish Bhagwati and Arvind Panagariya in a debate over the Mahatma Gandhi National Rural Employment Guarantee Scheme (MGNREGS),...

-The Hindu In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals. Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the...

-The Financial Express Besides better yield, mechanisation leads to a rise in labour employment   India is known as the land of agriculture, with a holding of nearly 157 million hectares of cultivable land, making our country the second-largest agricultural landholder in the world. With over 58% of the country's population depending on agriculture for earning livelihood, it is also the biggest employment avenue in the country. The Indian Green Revolution is regarded as...

-FirstPost.com Uncertainty over the supply of subsidised foodgrain to over 19 lakh families in Assam whose livelihoods are linked to work in the tea gardens is threatening to not only spark dissent among workers but has got the industry leaders worried. To understand the impact, consider the case of Deepak Daori and Monica Daori - both workers at Mokalbari Tea Estate in Dibrugarh district. "We are worried that the our monthly ration might...

-Business Standard This would be in addition to 348 drugs already under price ceiling The National Pharmaceutical Pricing Authority (NPPA) has capped the prices of another 52 essential drugs, in a move that could impact drug manufacturers Lupin, Cadila Healthcare and Merck. This is in addition to the 348 drugs already under a price ceiling. The majority of the 52 new drugs are antibiotics, painkillers and medicines used for treating cancer and skin...